Does Urodynamics Impact the Outcomes of Third-line Therapy of Refractory OAB (or Refractory Urgency Urinary Incontinence)?

2018 ◽  
Vol 13 (3) ◽  
pp. 158-161
Author(s):  
Marc P. Schneider ◽  
Andrea Tubaro ◽  
Fiona C. Burkhard
Keyword(s):  
Urinary Incontinence ◽  
Urgency Urinary Incontinence ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals H2-antagonist in IgE-mediated type I hypersensitivity reactions: what literature says so far?

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Matteo Borro ◽  
Simone Negrini ◽  
Andrew Long ◽  
Sharon Chinthrajah ◽  
Giuseppe Murdaca
Keyword(s):  
Receptor Antagonist ◽  
Inflammatory Responses ◽  
Type I ◽  
Line Therapy ◽  
H2 Antagonist ◽  
Amino Acid Histidine ◽  
Third Line Therapy ◽  
Ige Mediated ◽  
Third Line ◽  
Type I Hypersensitivity

AbstractHistamine is a monoamine synthesized from the amino acid histidine that is well-known for its role in IgE-mediated anaphylaxis but has shown pleiotropic effects on the immune system, especially in order to promote inflammatory responses. H1-receptor antagonist are common drugs used in mild/moderate allergic reactions whereas H2-receptor antagonist are commonly administered in gastric ulcer but showed some properties in allergy too. The EAACI guidelines for diagnosis and treatment of anaphylactic reactions recommend their use as third-line therapy in adjunct to H1-antagonists. The purpose of this article is to produce a complete summary of findings and evidence known so far about the usefulness of H2-receptor antagonist in allergic reactons.

scholarly journals Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

2012 ◽  
Vol 7 (10) ◽  
pp. 1594-1601 ◽  
Author(s):  
Vassiliki A. Papadimitrakopoulou ◽  
Jean-Charles Soria ◽  
Annette Jappe ◽  
Valentine Jehl ◽  
Judith Klimovsky ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

scholarly journals Fresh look on the urticaria problem.

2020 ◽  
Vol 17 (2) ◽  
pp. 33-43
Author(s):  
Alla O. Litovkina ◽  
Eugenii V. Smolnikov ◽  
Olga G. Elisyutina ◽  
Elena S. Fedenko
Keyword(s):  
Biological Treatment ◽  
First Line ◽  
Second Line Therapy ◽  
2Nd Generation ◽  
Line Therapy ◽  
H1 Antihistamines ◽  
Third Line Therapy ◽  
Third Line ◽  
Urticaria Treatment ◽  
Selection Of

Introduction. Nowadays urticaria is one of the most common diseases. According to the International Guidelines for the definition, classification, diagnosis and management of urticaria, 2nd-generation H1-antihistamines are recommended to be used as the first-line and second-line therapy. Omalizumab, a humanized monoclonal anti-IgE antibody, is assumed to be the third-line therapy in urticaria treatment. Summary. In this review we discuss the latest data on pathogenetic mechanisms of urticaria, focusing on the search of the new targets for the therapy. We represent the latest clinical trials of the new biological treatment for urticaria. Safety and efficiency of 4-folds higher therapeutical dose of the 2nd generation H1-antihistamines, and criteria for personalized selection of the antihistamines are discussed.

scholarly journals Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML

2015 ◽  
Vol 6 (2S) ◽  
pp. 15-18
Author(s):  
Giovanni Caocci ◽  
Sandra Atzeni ◽  
Giorgio La Nasa
Keyword(s):  
Pleural Effusion ◽  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Day Treatment ◽  
Skin Toxicity ◽  
Drug Dose ◽  
Molecular Response ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line

This case report describes a 74 year old male patient with low Sokal risk chronic myeloid leukemia (CML). Treatment was started four years ago with imatinib, 400 mg/day. The patient achieved complete hematologic response but, after 3 months of treatment, developed grade 3 skin toxicity. Imatinib was stopped and the patient was started on dasatinib, achieving complete cytogenetic and molecular response. Two months later, physical examination revealed bilateral gynecomastia. After 2 years of treatment the patient presented with pleural effusion and the drug dose was reduced but, following relapse of CML, therapy was switched to nilotinib, 800 mg/day. Treatment with nilotinib is currently ongoing and is well tolerated by the patient who is again in complete molecular response, with no signs of pleural effusion. Considering the growing availability of new and more potent tyrosine kinase inhibitors (TKI) it is important for the clinician to be aware of the possible inhibitory effects of these molecules against other members of the tyrosine kinase family. Safety of TKI in frail and elderly patients with CML is a fundamental goal. The results achieved in our patient show that nilotinib is safe and effective even when used as third line therapy.

scholarly journals Anesthetic Use In Status Epilepticus: A Concise Review

2020 ◽  
pp. 20-36
Author(s):  
Furkan M. Yilmaz ◽  
Lauren A. Igneri ◽  
Yasir A. Yilmaz ◽  
Evren Burakgazi-Dalkilic
Keyword(s):  
Status Epilepticus ◽  
Recent Literature ◽  
Refractory Status Epilepticus ◽  
Clinical Use ◽  
Concise Review ◽  
Refractory Status ◽  
Line Therapy ◽  
Agent Selection ◽  
Third Line Therapy ◽  
Third Line

The purpose of this review is to summarize the recent literature focusing on intravenous (IV) administration of commonly used anesthetics, including midazolam, pentobarbital/ thiopental, propofol, and ketamine in the treatment of status epilepticus (SE). Anesthetics should be reserved as third-line therapy for the treatment of SE when benzodiazepines and other second-line agents fail to terminate the seizure. We have reviewed the literature related to the treatment of status epilepticus, refractory status epilepticus, super-refractory status epilepticus, anesthetics, midazolam, pentobarbital/thiopental, propofol, and ketamine. This paper focuses on the pharmacology, dosages, major side effects, and clinical use of IV anesthetics in the treatment of SE with an emphasis on the developing literature supporting the use of ketamine for this indication. Based on the available literature, we propose recommendations for third-line agent selection in the management of SE.

Sign in / Sign up

Export Citation Format

Share Document